Predictors of depression in youth with Crohn disease.

作者: Jeffrey G. Clark , Arvind I. Srinath , Ada O. Youk , Margaret A. Kirshner , F. Nicole McCarthy

DOI: 10.1097/MPG.0000000000000277

关键词: EtanerceptDiseaseInfliximabAdalimumabPhysical therapyPsoriasis Area and Severity IndexPsoriatic arthritisInternal medicinePopulationMedicineSeverity of illness

摘要: Pediatric Crohn disease (CD) is a chronic, lifelong inflammatory bowel (IBD) that often involves an unpredictable cycle of flares and remissions. Symptoms can include abdominal pain, bloody diarrhea, weight loss, rectal bleeding (1). The patients with pediatric CD are at additional risk for the developmental problems, including growth retardation pubertal delay (2). In addition, this population also has high rate depression compared to community controls children other chronic illnesses (3). Several factors may contribute increased in IBD. It been shown activity interrelated (3,4). IBD-related morbidity through negative cognitive processing experience, which manifest as low self-esteem, feeling lack control over disease, or style, such rumination (5). Other related psychosocial stress associated coping physical illness decreased opportunities socialization (6). suggested be direct effect inflammation on brain (7,8). According hypothesis, some cases caused by systemic proinflammatory cytokines. One these cytokines, tumor necrosis factor-α (TNF-α), implicated both IBD (9,10). Basic clinical research already indicates TNF-α antagonism biological medications (eg, etanercept, adalimumab, infliximab) reduce depressive symptoms certain populations. For example, O’Connor et al (11) demonstrated mice pretreated etanercept resistant behavior following challenge immune-stimulator bacille Calmette-Guerin. Clinical randomized controlled trials have adalimumab yield significant improvements severity placebo (12,13). Notably, treated who experienced 75% greater reduction psoriasis area index score, even decrease (13). Another trial found psoriatic arthritis showed clinically relevant improvement mental component summary 36-Item Short-Form Health Survey treatment infliximab (14). Each illness; however, it unclear whether were more effects brain-based inflammation. This study cross-sectional examination relation between use CD. We hypothesized lower prevalence symptoms, would statistically when controlling potential mediators severity, sex, age, inflammation, steroid dose, socioeconomic status (SES). predictors was assessed, models constructed predict population.

参考文章(27)
Lesley A. Graff, John R. Walker, Charles N. Bernstein, Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflammatory Bowel Diseases. ,vol. 15, pp. 1105- 1118 ,(2009) , 10.1002/IBD.20873
Berthold Koletzko, Olivier Goulet, Joanne Hunt, Kathrin Krohn, Raanan Shamir, Parenteral Nutrition Guidelines Working Group, None, 1. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR). Journal of Pediatric Gastroenterology and Nutrition. ,vol. 41, pp. 1- 87 ,(2005) , 10.1097/01.MPG.0000181841.07090.F4
Matthew J. Hamilton, Scott B. Snapper, Richard S. Blumberg, Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance. Journal of Gastroenterology. ,vol. 47, pp. 1- 8 ,(2012) , 10.1007/S00535-011-0521-8
JOAN KAUFMAN, BORIS BIRMAHER, DAVID BRENT, UMA RAO, CYNTHIA FLYNN, PAULA MORECI, DOUGLAS WILLIAMSON, NEAL RYAN, Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial Reliability and Validity Data Journal of the American Academy of Child and Adolescent Psychiatry. ,vol. 36, pp. 980- 988 ,(1997) , 10.1097/00004583-199707000-00021
Yekta Dowlati, Nathan Herrmann, Walter Swardfager, Helena Liu, Lauren Sham, Elyse K. Reim, Krista L. Lanctôt, A Meta-Analysis of Cytokines in Major Depression Biological Psychiatry. ,vol. 67, pp. 446- 457 ,(2010) , 10.1016/J.BIOPSYCH.2009.09.033
Jeffrey S Hyams, George D Ferry, Francine S Mandel, Joyce D Gryboski, Phillip M Kibort, Barbara S Kirschner, Anne M Griffiths, Aubrey J Katz, Richard J Grand, John T Boyle, None, Development and validation of a pediatric Crohn's disease activity index. Journal of Pediatric Gastroenterology and Nutrition. ,vol. 12, pp. 439- 447 ,(1991)
St??phane Auvin, Florence Molini??, Corinne Gower-Rousseau, Franck Brazier, V??ronique Merle, Bruno Grandbastien, Raymond Marti, Eric Lerebours, Jean-Louis Dupas, Jean-Fr??d??ric Colombel, Jean-Louis Salomez, Antoine Cortot, Dominique Turck, Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988-1999). Journal of Pediatric Gastroenterology and Nutrition. ,vol. 41, pp. 49- 55 ,(2005) , 10.1097/01.MPG.0000162479.74277.86
Alan E. Kazdin, Debra Colbus, Antoinette Rodgers, Assessment of depression and diagnosis of depressive disorder among psychiatrically disturbed children Journal of Abnormal Child Psychology. ,vol. 14, pp. 499- 515 ,(1986) , 10.1007/BF01260519
Alan Menter, Matthias Augustin, James Signorovitch, Andrew P. Yu, Eric Q. Wu, Shiraz R. Gupta, Yanjun Bao, Parvez Mulani, The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial Journal of the American Academy of Dermatology. ,vol. 62, pp. 812- 818 ,(2010) , 10.1016/J.JAAD.2009.07.022
HAROLD C. SOX, Diagnostic Decision: The Erythrocyte Sedimentation Rate: Guidelines for Rational Use Annals of Internal Medicine. ,vol. 104, pp. 515- 523 ,(1986) , 10.7326/0003-4819-104-4-515